RR MedSciences awarded First Place
SAN FRANCISCO, JANUARY 2023 – Last month, US Capital Global Securities LLC, an affiliate of global private financial group US Capital, launched an investment opportunity of up to $250 million in InnoCom Bio Equities, Inc. (“InnoCom” or the “Company”). Headquartered in San Francisco, InnoCom focuses on bringing equity and early commercialization to innovative best-in-class life science ventures.
RR MedSciences awarded First Place by LiveScience PITCHFORCE SELECT for their Investor Presentation on April 13, 2023.
Pushing the Frontiers of Innovation in Healthcare
SAN FRANCISCO, JANUARY 2023 – Last month, US Capital Global Securities LLC, an affiliate of global private financial group US Capital, launched an investment opportunity of up to $250 million in InnoCom Bio Equities, Inc. (“InnoCom” or the “Company”). Headquartered in San Francisco, InnoCom focuses on bringing equity and early commercialization to innovative best-in-class life science ventures.
CEO, Jack E. Doty, Is Recognized at Health 2.0 Conference for Pushing the Frontiers of Innovation in Healthcare
Jack E. Doty, the CEO of InnoCom Bio Equities, Inc., participated as a speaker at the Health 2.0 Conference in Las Vegas and received an award for his outstanding contribution to the healthcare sector.
SAN FRANCISCO, JANUARY 2023 – Last month, US Capital Global Securities LLC, an affiliate of global private financial group US Capital, launched an investment opportunity of up to $250 million in InnoCom Bio Equities, Inc. (“InnoCom” or the “Company”). Headquartered in San Francisco, InnoCom focuses on bringing equity and early commercialization to innovative best-in-class life science ventures.
On December 21, Jack E. Doty, the CEO of InnoCom, presented at the Health 2.0 Conference in Las Vegas, participating on a panel entitled “Lessons Learned from the Pandemic: Leading in a Time of Crisis.” A premier event for the global healthcare community, the Health 2.0 Conference deliberates on ways to boost the global healthcare ecosystem by bringing the brightest minds in healthcare and wellness under one roof.
At an exclusive recognition session at the Conference, Mr. Doty was presented with an award for pushing the frontiers of innovation in healthcare. The Health 2.0 Conference Awards seek to recognize the smartest minds in the industry. They are intended to “honor a few such luminaries who have made impactful contributions and have been leading change in the healthcare sector.”
Speaking about InnoCom and its mission, Mr. Doty said: “When innovators are unable to attract capital for cutting-edge technologies, discoveries with blockbuster potential never make it to market. At InnoCom, we specialize in assisting entrepreneurs with deep scientific knowledge who are developing break-through innovations in the life sciences but who often lack the business experience, contacts, and financial expertise to secure the capital they need and to successfully take their cutting-edge technologies to commercialization in a regulated environment.”
Charles Towle, CEO at US Capital Global Securities, added: “InnoCom is looking to raise $250 million in equity to fund the pre-clinical, phase I, and phase II clinical trials of its portfolio companies, as well as funds to take these companies to market or to Big Pharma for licensing purposes. If you are interested in InnoCom, a rapidly expanding enterprise that is pushing the frontiers of innovation in healthcare, the opportunity to participate in this $250 million equity offering is now open to eligible investors.”
About InnoCom Bio Equity, Inc. InnoCom Bio Equities, Inc. is a California-based investment management and advisory firm providing services primarily to early-stage life sciences companies. The goal of the Company is to provide a tailored risk-averse investment platform where investors can gain access to exclusive life science portfolio companies, while also providing consulting and capital raise services to life science innovators.
www.innocombio.com
About US Capital
US Capital Global Securities LLC (“USCGS”) is the FINRA-member broker-dealer division of US Capital that acts as placement agent for growth-stage companies, projects, and investment funds. Since 1998, US Capital has been committed to providing lower middle market businesses and investors with sophisticated debt, equity, and investment opportunities usually available only to larger middle market companies and institutional investors, using the latest FinTech and RegTech innovation. US Capital entities manage direct investment funds and provide wealth management and capital raise services. USCGS or its affiliates may provide advice to, be compensated by, may have other business relationships with, or may from time to time acquire, hold or sell a position in the securities of the issuers mentioned herein. Any such offer or solicitation shall be made only pursuant to the confidential private placement memorandum. View USCGS’ Form CRS at www.uscapglobalsecurities.com/crs.html.
To learn more about this investment opportunity, email Pankaj Vashisth, Senior Vice President at US Capital Global Securities, at pv@uscapglobal.com or call +1 415-889-1034.
The Business Of Life Sciences with Jack Doty
Jack Doty has served as a member of numerous boards of directors, and as an officer in numerous companies. He has substantial experience advising growing life sciences, manufacturing and distribution companies. He has particular expertise in Infrastructure Development and Maintenance, C-Level Advisory, and Capital Introduction and Coordination.
Jack Doty has served as a member of numerous boards of directors, and as an officer in numerous companies. He has substantial experience advising growing life sciences, manufacturing and distribution companies. He has particular expertise in Infrastructure Development and Maintenance, C-Level Advisory, and Capital Introduction and Coordination.
Jack is currently the Chairman and Chief Executive Officer of InnoCom Bio Equities, a Life Sciences Special Purpose Vehicle investment and advising firm. As Founding President of the San Francisco Chapter of the Private Director Association, he built membership from and original 6 to 140 members, and has personally held numerous directorships: Vice Chairman, Granny Goose Foods, Inc.; Chairman, Hoopers Confections, Inc., Chairman, Metro Pacific Corporation; Director, San Francisco Chamber of Commerce Foundation; Director, San Francisco Chapter of Association for Corporate Growth; Director, Coalition for Better Housing; Director, San Francisco Chapter of Institute of Management Accountants. As a member of California Governor Jerry Brown’s Subdivision Advisory Committee, he established and chaired 148 separate boards of directors.
Jack’s career has ranged from entrepreneurial startups to major company turn-a-rounds. As a fractional C-Level Executive, he currently is business advisor to the CEO and CBDO at California Life Sciences Association, fractional CFO of Trove Therapeutics, fractional CFO of Outbreaker Solutions and Head of Finance of Teclison Limited. A company he headed built 248-unit Post Street Towers in San Francisco. He performed as Vice Chairman, Director and CFO of $100 million Granny Goose Foods, taking it from a $3 million loss to a $5 million profit. He performed as acting CFO of $50 million Honolulu Shipyards, spearheading the team that took the company out of pending foreclosure, refinanced it and led it through re-organization to profitability. He has successfully performed as Acting CFO and COO of a branded national Whole Foods level importer, as Acting CFO of an international federally funded non-profit education foundation, as financing consultant for several emerging companies, and as Managing Director for Finance of a Private Equity Fund. Jack now directs his considerable business skills and experience to Capital Introduction, C-Level Advisory and Board of Director seats.
Source: The Deal Scout